Suppr超能文献

肝素钠对慢性肾脏病大鼠肾性骨营养不良和血管钙化的影响。

Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.

机构信息

Renal Division, Peking University First Hospital, Beijing, China; Peking University Institute of Nephrology, Beijing, China; Key Laboratory of Renal Disease, Ministry of Health, Beijing, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Peking University, Ministry of Education, Beijing, China.

出版信息

Bone. 2014 Jan;58:168-76. doi: 10.1016/j.bone.2013.10.010. Epub 2013 Oct 18.

Abstract

Unfractionated heparin (UFH) is the most widely used anticoagulant in hemodialysis for chronic kidney disease (CKD) patients. Many studies have verified that UFH can induce bone loss in subjects with normal bone, but few have focused on its effect on renal osteodystrophy. We therefore investigated this issue in adenine-induced CKD rats. As CKD also impairs mineral metabolism systemically, we also studied the impacts of UFH on serum markers of CKD-mineral and bone disorder (CKD-MBD) and vascular calcification. We administered low and high doses of UFH (1U/g and 2U/g body weight, respectively) to CKD rats and compared them with CKD controls. At sacrifice, the serum markers of CKD-MBD did not significantly differ among the two UFH CKD groups and the CKD control group. The mean bone mineral densities (BMDs) of the total femur and a region of interest (ROI) constituted of trabecular and cortical bone were lower in the high-dose UFH (H-UFH) CKD group than in the CKD control group (P<0.05 and P<0.01, respectively). The BMD of the femoral ROI constituted of cortical bone did not differ between the H-UFH CKD group and the CKD control group. Histomorphometrical changes in the CKD rats indicated secondary hyperparathyroidism, and the femoral trabecular bone volume, but not cortical bone volume, significantly decreased with increasing UFH dose. The same decreasing trend was found in osteoblast parameters, and an increasing trend was found in osteoclast parameters; however, most differences were not significant. Moreover, no distinct statistical differences were found in the comparison of vascular calcium or phosphorus content among the CKD control group and the two UFH CKD groups. Therefore, we concluded that UFH could induce bone loss in CKD rats with secondary hyperparathyroidism, mainly by reducing the trabecular volume and had little effect on cortical bone volume. The underlying mechanism might involve inhibition of osteoblast activity and promotion of osteoclast activity by UFH. We did not find any effect of UFH on vascular calcification in CKD rats with secondary hyperparathyroidism.

摘要

未分级肝素 (UFH) 是慢性肾脏病 (CKD) 患者血液透析中最常用的抗凝剂。许多研究已经证实 UFH 可以在正常骨骼的受试者中引起骨丢失,但很少有研究关注其对肾性骨营养不良的影响。因此,我们在腺嘌呤诱导的 CKD 大鼠中研究了这个问题。由于 CKD 还会全身性地损害矿物质代谢系统,我们还研究了 UFH 对 CKD 矿物质和骨代谢紊乱 (CKD-MBD) 和血管钙化的血清标志物的影响。我们给 CKD 大鼠分别给予低剂量和高剂量的 UFH(1U/g 和 2U/g 体重),并将它们与 CKD 对照组进行比较。在处死时,两个 UFH-CKD 组与 CKD 对照组之间的 CKD-MBD 血清标志物没有显著差异。总股骨和包含骨小梁和皮质骨的感兴趣区域 (ROI) 的平均骨矿物质密度 (BMD) 在高剂量 UFH (H-UFH) CKD 组中低于 CKD 对照组(分别为 P<0.05 和 P<0.01)。H-UFH CKD 组与 CKD 对照组之间的股骨 ROI 皮质骨的 BMD 没有差异。CKD 大鼠的组织形态计量学变化表明继发甲状旁腺功能亢进,并且随着 UFH 剂量的增加,股骨小梁骨量而非皮质骨量显著减少。在成骨细胞参数中发现了相同的下降趋势,在破骨细胞参数中发现了上升趋势;然而,大多数差异并不显著。此外,在 CKD 对照组和两个 UFH-CKD 组之间的血管钙或磷含量的比较中,没有发现明显的统计学差异。因此,我们得出结论,UFH 可能会在继发甲状旁腺功能亢进的 CKD 大鼠中引起骨丢失,主要是通过减少小梁体积,对皮质骨体积几乎没有影响。UFH 可能通过抑制成骨细胞活性和促进破骨细胞活性来发挥作用。我们没有发现 UFH 对继发甲状旁腺功能亢进的 CKD 大鼠血管钙化有任何影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验